Japan · Delayed Price · Currency is JPY Fuji Pharma Statistics
Total Valuation
Fuji Pharma has a market cap or net worth of JPY 65.94 billion. The enterprise value is 93.02 billion.
| Market Cap | 65.94B |
| Enterprise Value | 93.02B |
Important Dates
The next estimated earnings date is Thursday, May 7, 2026.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | Mar 30, 2026 |
Share Statistics
Fuji Pharma has 26.11 million shares outstanding. The number of shares has increased by 0.50% in one year.
| Current Share Class | 26.11M |
| Shares Outstanding | 26.11M |
| Shares Change (YoY) | +0.50% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 38.78% |
| Owned by Institutions (%) | 12.66% |
| Float | 13.31M |
Valuation Ratios
The trailing PE ratio is 26.46 and the forward PE ratio is 17.21.
| PE Ratio | 26.46 |
| Forward PE | 17.21 |
| PS Ratio | 1.21 |
| PB Ratio | 1.38 |
| P/TBV Ratio | 1.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 39.87 |
| EV / Sales | 1.70 |
| EV / EBITDA | 8.81 |
| EV / EBIT | 14.25 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.57, with a Debt / Equity ratio of 0.64.
| Current Ratio | 1.57 |
| Quick Ratio | 0.83 |
| Debt / Equity | 0.64 |
| Debt / EBITDA | 2.88 |
| Debt / FCF | n/a |
| Interest Coverage | 19.31 |
Financial Efficiency
Return on equity (ROE) is 4.88% and return on invested capital (ROIC) is 7.41%.
| Return on Equity (ROE) | 4.88% |
| Return on Assets (ROA) | 4.31% |
| Return on Invested Capital (ROIC) | 7.41% |
| Return on Capital Employed (ROCE) | 10.40% |
| Weighted Average Cost of Capital (WACC) | 4.58% |
| Revenue Per Employee | 31.01M |
| Profits Per Employee | 1.33M |
| Employee Count | 1,760 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 1.49 |
Taxes
In the past 12 months, Fuji Pharma has paid 491.00 million in taxes.
| Income Tax | 491.00M |
| Effective Tax Rate | 17.39% |
Stock Price Statistics
The stock price has increased by +78.90% in the last 52 weeks. The beta is 0.37, so Fuji Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.37 |
| 52-Week Price Change | +78.90% |
| 50-Day Moving Average | 2,165.74 |
| 200-Day Moving Average | 1,704.75 |
| Relative Strength Index (RSI) | 68.58 |
| Average Volume (20 Days) | 179,340 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Fuji Pharma had revenue of JPY 54.57 billion and earned 2.33 billion in profits. Earnings per share was 95.47.
| Revenue | 54.57B |
| Gross Profit | 22.28B |
| Operating Income | 6.53B |
| Pretax Income | 2.82B |
| Net Income | 2.33B |
| EBITDA | 10.56B |
| EBIT | 6.53B |
| Earnings Per Share (EPS) | 95.47 |
Balance Sheet
The company has 3.39 billion in cash and 30.47 billion in debt, with a net cash position of -27.08 billion or -1,037.15 per share.
| Cash & Cash Equivalents | 3.39B |
| Total Debt | 30.47B |
| Net Cash | -27.08B |
| Net Cash Per Share | -1,037.15 |
| Equity (Book Value) | 47.95B |
| Book Value Per Share | 1,959.36 |
| Working Capital | 18.38B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 4.04B |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 40.82%, with operating and profit margins of 11.96% and 4.27%.
| Gross Margin | 40.82% |
| Operating Margin | 11.96% |
| Pretax Margin | 5.17% |
| Profit Margin | 4.27% |
| EBITDA Margin | 19.36% |
| EBIT Margin | 11.96% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 47.00, which amounts to a dividend yield of 1.98%.
| Dividend Per Share | 47.00 |
| Dividend Yield | 1.98% |
| Dividend Growth (YoY) | 14.12% |
| Years of Dividend Growth | 4 |
| Payout Ratio | n/a |
| Buyback Yield | -0.50% |
| Shareholder Yield | 1.50% |
| Earnings Yield | 3.54% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 27, 2018. It was a forward split with a ratio of 2.
| Last Split Date | Jun 27, 2018 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Fuji Pharma has an Altman Z-Score of 2.02 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.02 |
| Piotroski F-Score | 5 |